Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice.
As differentiated (follicular and papillary) thyroid cancer (DTC) may recur years after initial treatment, follow-up of patients with DTC is long term. However, this population has changed, with more individuals being discovered at an earlier stage of disease, so that previous follow-up protocols based mostly on data from high-risk patients no longer apply. We have proposed, in a previous issue of this Journal, an improved protocol for the follow-up of low-risk patients with DTC based on the findings of recent studies. We report here the case of a paradigmatic patient with papillary thyroid carcinoma, with the goal of illustrating the benefits of applying this algorithm in routine clinical practice. We also offer expanded and additional comments on various issues in the management of DTC.
Schlumberger
Martin
M
Service de Médicine Nucléaire, Institut Gustave Roussy, 94805 Villejuif, France. schlumbg@igr.fr
Pacini
Furio
F
Wiersinga
Wilmar M
WM
Toft
Antony
A
Smit
Johannes W A
JW
Sanchez Franco
Franco
F
Lind
Peter
P
Limbert
Edward
E
Jarzab
Barbara
B
Jamar
François
F
Duntas
Leonidas
L
Cohen
Ohad
O
Berg
Gertrud
G
D000328:Adult; D000465:Algorithms; D002291:Carcinoma, Papillary / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D011877:Radionuclide Imaging; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D013965:Thyroidectomy; D013974:Thyroxine / Q000627:therapeutic use
D007457:Iodine Radioisotopes; D013974:Thyroxine